Cargando…
MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features
BACKGROUND: MicroRNA (miRNA) expression is known to be deregulated in ovarian carcinomas. However, limited data is available about the miRNA expression pattern for the benign or borderline ovarian tumors as well as differential miRNA expression pattern associated with histological types, grades or c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449188/ https://www.ncbi.nlm.nih.gov/pubmed/22925189 http://dx.doi.org/10.1186/1477-7819-10-174 |
_version_ | 1782244321438728192 |
---|---|
author | Lee, Heejeong Park, Chul Soo Deftereos, Georgios Morihara, Janice Stern, Joshua E Hawes, Stephen E Swisher, Elizabeth Kiviat, Nancy B Feng, Qinghua |
author_facet | Lee, Heejeong Park, Chul Soo Deftereos, Georgios Morihara, Janice Stern, Joshua E Hawes, Stephen E Swisher, Elizabeth Kiviat, Nancy B Feng, Qinghua |
author_sort | Lee, Heejeong |
collection | PubMed |
description | BACKGROUND: MicroRNA (miRNA) expression is known to be deregulated in ovarian carcinomas. However, limited data is available about the miRNA expression pattern for the benign or borderline ovarian tumors as well as differential miRNA expression pattern associated with histological types, grades or clinical stages in ovarian carcinomas. We defined patterns of microRNA expression in tissues from normal, benign, borderline, and malignant ovarian tumors and explored the relationship between frequently deregulated miRNAs and clinicopathologic findings, response to therapy, survival, and association with Her-2/neu status in ovarian carcinomas. METHODS: We measured the expression of nine miRNAs (miR-181d, miR-30a-3p, miR-30c, miR-30d, miR-30e-3p, miR-368, miR-370, miR-493-5p, miR-532-5p) in 171 formalin-fixed, paraffin-embedded ovarian tissue blocks as well as six normal human ovarian surface epithelial (HOSE) cell lines using Taqman-based real-time PCR assays. Her-2/neu overexpression was assessed in ovarian carcinomas (n = 109 cases) by immunohistochemistry analysis. RESULTS: Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues. Expression of miR-532-5p was significantly lower in borderline than in benign tissues. Among ovarian carcinomas, expression of four miRNAs (miR-30a-3p, miR-30c, miR-30d, miR-30e-3p) was lowest in mucinous and highest in clear cell samples. Expression of miR-30a-3p was higher in well-differentiated compared to poorly differentiated tumors (P = 0.02), and expression of miR-370 was higher in stage I/II compared to stage III/IV samples (P = 0.03). In multivariate analyses, higher expression of miR-181d, miR-30c, miR-30d, and miR-30e-3p was associated with significantly better disease-free or overall survival. Finally, lower expression of miR-30c, miR-30d, miR-30e-3p and miR-532-5p was significantly associated with overexpression of Her-2/neu. CONCLUSIONS: Aberrant expression of miRNAs is common in ovarian tumor suggesting involvement of miRNA in ovarian tumorigenesis. They are associated with histology, clinical stage, survival and oncogene expression in ovarian carcinoma. |
format | Online Article Text |
id | pubmed-3449188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34491882012-09-24 MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features Lee, Heejeong Park, Chul Soo Deftereos, Georgios Morihara, Janice Stern, Joshua E Hawes, Stephen E Swisher, Elizabeth Kiviat, Nancy B Feng, Qinghua World J Surg Oncol Research BACKGROUND: MicroRNA (miRNA) expression is known to be deregulated in ovarian carcinomas. However, limited data is available about the miRNA expression pattern for the benign or borderline ovarian tumors as well as differential miRNA expression pattern associated with histological types, grades or clinical stages in ovarian carcinomas. We defined patterns of microRNA expression in tissues from normal, benign, borderline, and malignant ovarian tumors and explored the relationship between frequently deregulated miRNAs and clinicopathologic findings, response to therapy, survival, and association with Her-2/neu status in ovarian carcinomas. METHODS: We measured the expression of nine miRNAs (miR-181d, miR-30a-3p, miR-30c, miR-30d, miR-30e-3p, miR-368, miR-370, miR-493-5p, miR-532-5p) in 171 formalin-fixed, paraffin-embedded ovarian tissue blocks as well as six normal human ovarian surface epithelial (HOSE) cell lines using Taqman-based real-time PCR assays. Her-2/neu overexpression was assessed in ovarian carcinomas (n = 109 cases) by immunohistochemistry analysis. RESULTS: Expression of four miRNAs (miR-30c, miR-30d, miR-30e-3p, miR-370) was significantly different between carcinomas and benign ovarian tissues as well as between carcinoma and borderline tissues. An additional three miRNAs (miR-181d, miR-30a-3p, miR-532-5p) were significantly different between borderline and carcinoma tissues. Expression of miR-532-5p was significantly lower in borderline than in benign tissues. Among ovarian carcinomas, expression of four miRNAs (miR-30a-3p, miR-30c, miR-30d, miR-30e-3p) was lowest in mucinous and highest in clear cell samples. Expression of miR-30a-3p was higher in well-differentiated compared to poorly differentiated tumors (P = 0.02), and expression of miR-370 was higher in stage I/II compared to stage III/IV samples (P = 0.03). In multivariate analyses, higher expression of miR-181d, miR-30c, miR-30d, and miR-30e-3p was associated with significantly better disease-free or overall survival. Finally, lower expression of miR-30c, miR-30d, miR-30e-3p and miR-532-5p was significantly associated with overexpression of Her-2/neu. CONCLUSIONS: Aberrant expression of miRNAs is common in ovarian tumor suggesting involvement of miRNA in ovarian tumorigenesis. They are associated with histology, clinical stage, survival and oncogene expression in ovarian carcinoma. BioMed Central 2012-08-27 /pmc/articles/PMC3449188/ /pubmed/22925189 http://dx.doi.org/10.1186/1477-7819-10-174 Text en Copyright ©2012 Lee et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Lee, Heejeong Park, Chul Soo Deftereos, Georgios Morihara, Janice Stern, Joshua E Hawes, Stephen E Swisher, Elizabeth Kiviat, Nancy B Feng, Qinghua MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features |
title | MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features |
title_full | MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features |
title_fullStr | MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features |
title_full_unstemmed | MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features |
title_short | MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features |
title_sort | microrna expression in ovarian carcinoma and its correlation with clinicopathological features |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3449188/ https://www.ncbi.nlm.nih.gov/pubmed/22925189 http://dx.doi.org/10.1186/1477-7819-10-174 |
work_keys_str_mv | AT leeheejeong micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT parkchulsoo micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT deftereosgeorgios micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT moriharajanice micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT sternjoshuae micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT hawesstephene micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT swisherelizabeth micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT kiviatnancyb micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures AT fengqinghua micrornaexpressioninovariancarcinomaanditscorrelationwithclinicopathologicalfeatures |